The aim of the study is to qualitatively and quantitatively compare the diagnostic value of diffusion-weighted (DW) magnetic resonance (MR) imaging based on standard single-shot echo-planar imaging (ss-EPI) and readout-segmented echo-planar imaging in patients with prostate cancer at 3.0 Tesla. All patients referred with suspected prostate cancer, underwent multiparametric MR imaging (mpMRI) using our 3.0-T MR imager (Magnetom Skyra, Siemens Healthineers, Erlangen, Germany). In all patients, DW imaging was carried out first using ss-EPI and later using readout segmentation of long variable echo-trains (RESOLVE) sequence. RESOLVE is a type of multishot readout-segmented echo echo-planar imaging (rs-EPI) technique with an additional two-dimensional navigator for robust correction of motion-induced phase errors. Two independent readers visually assessed image quality, lesion conspicuity, and geometric distortions using a 5-point Likert scale. Image properties, such as signal-to-noise ratio, contrast-to-noise ratio, apparent diffusion coefficient (ADC) values, were also quantified. Both readers demonstrated good-to-excellent interreader agreement for the qualitative image-quality parameters. RESOLVE demonstrated significantly higher scores for overall image quality, lesion conspicuity, and reduced geometric distortion compared with ss-EPI (all p < 0.05). Quantitatively, the mean SNR was significantly higher with RESOLVE than with ss-EPI (11.8 ± 4.3 vs. 9.2 ± 4.7, p = 0.021). The mean contrast-to-noise ratio was also higher with RESOLVE (3.7 ± 4.2 vs. 3.0 ± 3.0), although the difference did not reach statistical significance (p = 0.055). Mean ADC was lower with RESOLVE than with ss-EPI (0.717 ± [SD] × 10 − 3 vs. 0.821 ± [SD] × 10 − 3 mm2/s), with no statistically significant difference (p = 0.058). Compared with conventional ss-EPI, the use of rs-EPI for the acquisition of prostate diffusion-weighted imaging (DWI) resulted in significantly enhanced anatomical delineation, lesion conspicuity, and reduced geometric distortion. Therefore, rs-EPI could be an alternative to or replacement for ss-EPI for acquiring prostate DWI at 3.0 Tesla.
No takes yet. Share an insight, caveat, or question.
Veerappan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: